Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy

15 Mar 2016

Abstract excerpt

Blockade of immune checkpoints has emerged as key strategy in the development of effective cancer therapies. In contrast to cell surface checkpoints like CTLA-4 and PD-1, however, additional cancer therapeutic targets are located inside the effector immune cells. Targeting these alternative checkpoints in cancer immunotherapy with the goal to strengthen the patient's immune system are likely to extend the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26992368
DOI: 10.1016/j.imlet.2016.03.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapyPMID 26992368Read ↗

Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6Semantic proximity Read ↗

Insights into the emerging immune checkpoint NR2F6 in cancer immunitySemantic proximity Read ↗

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockadeSemantic proximity Read ↗

Melanoma-intrinsic NR2F6 activity regulates anti-tumor immunitySemantic proximity Read ↗

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapySemantic proximity Read ↗

NR2F6 promotes the malignant progression of neuroblastoma as an indicator of poor prognosisSemantic proximity Read ↗

AGO2 mediates immunotherapy failure via suppressing tumor IFN-gamma response-dependent CD8+ T cell immunitySemantic proximity Read ↗

ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancerSemantic proximity Read ↗

NRIR promotes immune escape in hepatocellular cancer by regulating IFNγ-induced PD-L1 expressionSemantic proximity Read ↗

TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapySemantic proximity Read ↗

Activation of Cytotoxic Lymphocytes Through CD6 Enhances Killing of Cancer CellsSemantic proximity Read ↗

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.